摘要
目的:探讨肝移植受者术后使用五酯胶囊提升他克莫司浓度与供肝CYP3A5基因多态性是否存在相关性。方法:肝移植术后,40例连续服用五酯胶囊6个月的患者为试验组.46例未服用五酯胶囊患者为对照组,计算在术后15d,1个月,3个月,6个月时他克莫司C0/D值。同时,采用PCR-RFLP(聚合酶链反应)方法对CYP3A5基因型进行检测。结果:不考虑供肝CYP3A5基因情况下,在各时间点试验组与对照组他克莫司C0/D值比较,差异有统计学意义(P<0.05)。供肝CYP3A5基因为1/1型和1/3型患者中,五酯胶囊能显著提高各时间点他克莫司C0/D值(P<0.01);但在CYP3A53/3型中,五酯胶囊对他克莫司C0/D值未见明显影响(P>0.05)。结论:五酯胶囊提升FK506血药浓度与供肝CYP3A5基因多态性有显著相关性。当使用五酯胶囊作为他克莫司的增效剂时,应该考虑CYP3A5基因多态性。
Objective: To investigate whether the use of Wuzhi Capsule to increase the concentration of tacrolimus in liver transplant recipients is related to the CYP3 A5 gene polymorphism of donor liver. Methods: After liver transplantation, 40 patients who took Wuzhi Capsule for 6 months as the experimental group and 46 patients who did not take Wuzhi Capsule as the control group. The C0/D value of tacrolimus was calculated at 15 days, 1 month, 3 months and 6 months after operation. At the same time, the CYP3 A5 genotype was detected by PCR-RFLP. Results: Without considering the CYP3 A5 gene of donor liver, there was significant difference in the C0/D value of tacrolimus between the experimental group and the control group at each time(P<0.05). Among the patients with CYP3 A5 gene type 1/1 and 1/3 of donor liver, Wuzhi Capsule could significantly increase the C0/D value of tacrolimus at each time point(P<0.01);in gene type 3/3, Wuzhi Capsule had no significant effect on the C0/D value of tacrolimus(P>0.05). Conclusion: There was a significant correlation between the increase of FK506 concentration by Wuzhi Capsule and the CYP3 A5 gene polymorphism of donor liver. CYP3 A5 gene polymorphism should be considered when Wuzhi Capsule is used as a synergist of tacrolimus.
作者
马景胜
杨文涛
朱红飞
武雅君
MA Jingsheng;YANG Wentao;ZHU Hongfei;WU Yajun(Department of Organ Transplantation,Second Affiliated Hospital of Nanchang University,Nanchang,330038,China;College of Medical Technology,Nanchang Medical College)
出处
《中国中西医结合消化杂志》
CAS
2022年第4期271-274,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
基金
江西省中医药管理局一般项目(No:2020A0286)
江西省卫生健康委员会普通项目(No:202130436)。
